Get the Stockscreener App
3.0973
2.31%
0.0673
Aptevo Therapeutics Inc stock is traded at $3.0973, with a volume of 185.99K.
It is up +2.31% in the last 24 hours and down -25.66% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$3.03
Open:
$3.09
24h Volume:
185.99K
Relative Volume:
0.08
Market Cap:
$9.96M
Revenue:
$12.99M
Net Income/Loss:
$-23.72M
P/E Ratio:
-0.0318
EPS:
-97.2514
Net Cash Flow:
$-23.28M
1W Performance:
+5.08%
1M Performance:
-25.66%
6M Performance:
-96.56%
1Y Performance:
-99.05%
1-Day Range:
$3.0114
$3.18
1-Week Range:
$2.86
$3.18
52-Week Range:
$2.81
$381.10
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
3.09 | 9.51M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.45 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.49 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.81 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
567.36 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.09 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
What drives Aptevo Therapeutics Inc. stock priceMarket-beating performance - jammulinksnews.com
Is Aptevo Therapeutics Inc. a good long term investmentOutstanding investment returns - jammulinksnews.com
Aptevo Therapeutics Inc. Stock Analysis and ForecastFastest-growing stock picks - jammulinksnews.com
What analysts say about Aptevo Therapeutics Inc. stockAccelerated profit realization - jammulinksnews.com
Aptevo Meets Nasdaq $2.5M Equity Requirement - MSN
What makes Aptevo Therapeutics Inc. stock price move sharplyFree Access to Community - Newser
Why Aptevo Therapeutics Inc. stock attracts strong analyst attentionFree Elite Traders Group - Newser
How Aptevo Therapeutics Inc. stock performs during market volatility2x 3x 5x Pick Alert - Newser
10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey
Aptevo regains Nasdaq compliance following $15.9 million equity raise By Investing.com - Investing.com India
Aptevo Therapeutics Regains Nasdaq Compliance with Equity Raise - TipRanks
Aptevo regains Nasdaq compliance following $15.9 million equity raise - Investing.com
Aptevo Therapeutics Raises $15.9M to Meet Nasdaq Compliance - TipRanks
Aptevo (APVO) appoints Baker Tilly as auditor after Moss Adams merger - Stock Titan
Aptevo Therapeutics' 18.7% Plunge: What Drives a Volatile Day Without News? - AInvest
Benzinga Bulls And Bears: Circle, Sunrun, JetBlue — And Mideast Has Markets Nervous - Benzinga
Aptevo (APVO) appoints Baker Tilly as auditor after Moss Adams merger | C SEC FilingForm 424B2 - Stock Titan
Aptevo Therapeutics Surges 82% Amid No Fundamental News—What’s Driving the Spike? - AInvest
Top Small Cap Stocks Worth WatchingJune 18th - MarketBeat
Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga
Aptevo Therapeutics raises $8 million in registered direct offering - Investing.com Australia
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Aptevo Therapeutics (APVO) Secures $8M Through Direct Offering - GuruFocus
Aptevo Therapeutics announces $8M at-the-market equity offering with warrants; shares more than double - MSN
Aptevo Therapeutics raises $8 million in registered direct offering By Investing.com - Investing.com India
Why Is Micro-Cap Aptevo Stock Trading Higher On Wednesday?Aptevo Therapeutics (NASDAQ:APVO) - Benzinga
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules | APVO Stock News - GuruFocus
An early stage 85% remissions rate in AML drives Aptevo’s stock surge - BioWorld MedTech
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire
Aptevo Secures $8M Funding: Biotech Company Accelerates Cancer Drug Development Pipeline - Stock Titan
Aptevo Therapeutics stock soars after impressive AML treatment results - Investing.com
Aptevo Therapeutics stock soars after impressive AML treatment results By Investing.com - Investing.com Canada
Why did Aptevo Therapeutics Shares Skyrocket in Premarket Trading Today? - Tokenist
Aptevo Therapeutics Skyrockets on Game-Changing AML Drug News - RagingBull
Aptevo reports 85% remission rate in frontline AML trial By Investing.com - Investing.com Nigeria
Aptevo Therapeutics (APVO) Shows Promising Results in RAINIER Tr - GuruFocus
Aptevo Says Its Mipletamig Therapy Achieves 85% Remission Rate in Leukemia Patients; Shares Soar Pre-Bell - MarketScreener
Aptevo Therapeutics (APVO) Shows Promising Results in AML Trial - GuruFocus
Aptevo Therapeutics announces new clinical data from RAINIER trial - TipRanks
Aptevo announces clinical data from ongoing Phase 1b/2 RAINIER trial - TipRanks
Breakthrough AML Drug Achieves 85% Remission Rate: New Hope for Previously Untreatable Patients - Stock Titan
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML | APVO Stock News - GuruFocus
Aptevo Therapeutics Signs Equity Purchase Agreement - TipRanks
APVO Secures Roth Capital Partners as Exclusive Placement Agent - GuruFocus
Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Decreases By 55.0% - Defense World
Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High - MSN
Aptevo Participating in the BIO International Convention | APVO Stock News - GuruFocus
Aptevo Sends Business Development Team to BIO 2025: Major Partnership Opportunities Ahead - Stock Titan
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.03%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):